Wisconsin Discovery Portal

Researcher: Alan Attie

[ printable ]
Areas of Expertise
  • Molecular genetics of diabetes and insulin resistance
  • Mechanisms by which β-cells sense glucose and trigger insulin secretion
  • A novel gene responsible for biogenesis of insulin containing vesicles
  • Tomosyn-2, a protein involved in insulin exocytosis
  • Causal networks linking specific genes with diabetes phenotypes
  • Mapping gene loci that contribute to diabetes and obesity
  • Molecular biology of ß-cell proliferation
  • Cell biology of lipoprotein assembly
  • Cholesterol trafficking
Web Site Alan Attie's Department of Biochemistry Website
Curriculum Vitae (CV) Alan Attie's CV
Issued Patent(s)
  • 8,507,557 - Potentiators of insulin secretion, issued August 2013.
  • 7,816,075 - Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents, issued October 2010.
  • 7,442,500 - Methods of diagnosing susceptibility to obesity, issued October 2008.
  • 7,166,584 - Cholesterol transport gene, issued January 2007.
  • 6,987,001 - Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents, issued January 2006.
USPTO Published Applications
  • 20140378375 - Alpha/beta-polypeptide analogs of glucagon-like peptide 1, published December 2014.
  • 20130244932 - E-prostanoid receptor, ptger3, as a novel anti-diabetic therapeutic target, published September 2013.
  • 20120164154 - Method for increasing insulin sensitivity and for treating and preventing type 2 diabetes, published June 2012.
  • 20110287084 - Method for reducing body fat and increasing lean body mass by reducing stearoyl-coa desaturase 1 activity, published November 2011.
  • 20110071222 - Potentiators of insulin secretion, published March 2011.
Recent Publication(s)
  • Nat1 deficiency is associated with mitochondrial dysfunction and exercise intolerance in mice. Chennamsetty I, Coronado M, Contrepois K, Keller MP, Carcamo-Orive I, Sandin J, Fajardo G, Whittle AJ, Fathzadeh M, Snyder M, Reaven G, Attie AD, Bernstein D, Quertermous T, Knowles JW. Cell Rep. 2016 Oct 4;17(2):527-540. doi: 10.1016/j.celrep.2016.09.005.

  • Neucode proteomics reveals bap1 regulation of metabolism. Baughman JM, Rose CM, Kolumam G, Webster JD, Wilkerson EM, Merrill AE, Rhoads TW, Noubade R, Katavolos P, Lesch J, Stapleton DS, Rabaglia ME, Schueler KL, Asuncion R, Domeyer M, Zavala-Solorio J, Reich M, DeVoss J, Keller MP, Attie AD, Hebert AS, Westphall MS, Coon JJ, Kirkpatrick DS, Dey A. Cell Rep. 2016 Jul 12;16(2):583-95. doi: 10.1016/j.celrep.2016.05.096. Epub 2016 Jun 30.

  • The dissection of expression quantitative trait locus hotspots. Tian J, Keller MP, Broman AT, Kendziorski C, Yandell BS, Attie AD, Broman KW. Genetics. 2016 Apr;202(4):1563-74. doi: 10.1534/genetics.115.183624. Epub 2016 Feb 2.

  • Unexpected partial correction of metabolic and behavioral phenotypes of Alzheimer's app/psen1 mice by gene targeting of diabetes/Alzheimer's-related sorcs1. Knight EM, Ruiz HH, Kim SH, Harte JC, Hsieh W, Glabe C, Klein WL, Attie AD, Buettner C, Ehrlich ME, Gandy S. Acta Neuropathol Commun. 2016 Feb 25;4:16. doi: 10.1186/s40478-016-0282-y.

View Alan Attie's publications at PubMed.
Recent Artistic Works
  • Intra-University Collaboration: Chemistry, Biomolecular Chemistry, Statistics, Biostatistics and Medical Informatics, Surgery
  • University of Texas, Internal Medicine
  • Duke University, Pharmacology
  • University of Pennsylvania, Medicine
Research Tools
  • Microarray technology
Research Facilities
  • Alan Attie Laboratory
E-mail Address [email protected]
Phone Number 608-262-1372
Current University UW–Madison
Department Biochemistry
Title Professor
Other Appointments
Address Line 1 543A DeLuca Biochemistry Laboratories
Address Line 2 433 Babcock Drive
City Madison
State WI
Zip Code 53706
Bachelor's Degree B.S., UW–Madison
Master's Degree
PhD Ph.D., University of California, San Diego
Other Degrees
Technologies Available for Licensing Compounds to Treat Hyperlipidemia and Fatty Liver Disease

Screening Assays Based on Stearoyl-CoA Desaturase for Diseases Related to Serum Levels of Triglycerides and VLDL

Non-Natural Peptides for Treating Diabetes

Treating and Preventing Diabetes by Targeting EP3 Receptor